Benralizumab - Kyowa Hakko Kirin/MedImmune

Drug Profile

Benralizumab - Kyowa Hakko Kirin/MedImmune

Alternative Names: Benra; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK 4563; MEDI-563

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioWa
  • Developer AstraZeneca; Cincinnati Children's Hospital Medical Center; Kyowa Hakko; Kyowa Hakko Kirin; MedImmune; National Jewish Medical and Research Center
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease; Nasal polyps
  • Phase II Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis
  • Phase I/II Eosinophilic gastroenteritis

Most Recent Events

  • 22 Jun 2018 AstraZeneca plans the phase III PONENTE trial for Asthma in USA, Argentina, Russia, Colombia and Germany, in July 2018 (NCT03557307)
  • 10 Apr 2018 AstraZeneca and MedImmune complete phase III GALATHEA trial in Chronic obstructive pulmonary disease in US, Canada, the UK, Austria, Czech Republic, Hungary, The Netherlands, Germany, Italy, Poland, Russia, Romania, Spain, South Africa and Switzerland (NCT02138916)
  • 09 Apr 2018 AstraZeneca completes the phase III TERRANOVA trial for Chronic obstructive pulmonary disease in USA, Argentina, Colombia, Peru, Australia, Belgium, Bulgaria, France, Denmark, Sweden, Poland, Norway, Philippines, Taiwan, Vietnam, Turkey, Ukraine, Israel, Croatia, Slovenia, Brazil, Chile, Mexico, New Zealand, Serbia and Thailand (SC) (NCT02155660)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top